Xanodyne Announces Appointment of Mr. Vaughn M. Kailian of MPM Capital to the Board of Directors

NEWPORT, Ky., June 12 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce the appointment of Mr. Vaughn M. Kailian to the Company's Board of Directors. Mr. Kailian is currently Managing Director of MPM Capital and brings extensive commercial and general management experience to X...

Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs

IRVING, Texas, March 30 /PRNewswire-FirstCall/ -- Patients undergoing cancer treatment reported that using Regenecare hydrogel significantly reduced the pain and itching associated with the sometimes-severe skin rashes caused by anti-cancer drugs. Conducted by the Western University of H...

iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board

...r reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, mpm Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic ...

CombinatoRx and Neuromed Sign Merger Agreement

...hairman; Mark Corrigan, MD, EVP, Research & Development, Sepracor Inc.; Sally Crawford, former COO of Healthsource; Todd Foley, Managing Director, mpm Capital; William Hunter, MD, MSc, Chairman of the Board, President & CEO, Angiotech Pharmaceuticals Inc.; Michael Kauffman, MD, Ph.D., CMO, Proteo...

Horse Study: RBC Life Sciences' Antioxidant, Microhydrin, Reduced Lactic Acid Buildup and Improved Hydration During Strenuous Exercise

...-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its mpm Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescri...

All Seven Members of RBC Life Sciences' Board of Directors Were Re-Elected During the Company's 2009 Annual Shareholders Meeting

...th L. Sabot, senior vice president of operations; Paul Miller, president of mpm Medical, Inc.; Joseph P. Phillip, independent director; and Robert A. Kaise...pulation of consumers seeking wellness and a healthy lifestyle. Under its mpm Medical brand, RBC Life Sciences also develops and markets to health care...

Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing

... member of the Company's Board of Directors. In addition to Mr. Valentino's announcement, Xanodyne completed an equity financing of $38 million led by mpm Capital. Current investors' participation also included; AIG Investments' sponsored funds, Aisling Capital, Blue Chip Venture Company, Essex Woodlands...

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

...ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, mpm Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE ) as well as Hamilton BioVentures and California Technology Partners. ...

RBC Life Sciences' North American Nutritional Supplements and Medical Products Sales Increased, Year Over Year, During the First Quarter of 2009

...on during the first quarter of 2008. The company's mpm Medical, Inc., brand saw its wound care and pain m...e generated from increased sales. "Meanwhile, mpm Medical's pain management and wound care products ...king wellness and a healthy lifestyle. Under its mpm Medical brand, RBC Life Sciences also develops a...

Surface Logix Raises $20 Million in Financing and Starts Phase 2b Clinical Trial of SLx-4090 in Dyslipidemia and Diabetes

...BM BioVentures, Healthcare Focus, Intel Capital, Saudi Venture Development Company, Unilever Technology Ventures and Venrock Associates. In addition, mpm Capital participated as a new investor. On top of the equity round, $5 million was raised through a venture loan from Silicon Valley Bank. "Th...

MPM in Medical Technology

Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million

... All existing institutional investors participated in the financing, led by mpm Bio IV NVS Strategic Fund and including mpm Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partner...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...ted to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, mpm Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation. For additional information, please contact us....

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

...ted to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, mpm Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation. For additional information, please contact u...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

...ted to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, mpm Capital, Hunt BioVentures, Boston Medical Investors, and Silicon Valley Capital Partners. For additional information, access our Web site at http://w...

First Human Implant of New Archus Orthopedics Facet Replacement System

...plants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. Archus has received venture capital funding from mpm Capital, InterWest Partners, Polaris Venture Partners and Johnson & Johnson Development Corporation, in cooperation with DePuy Spine. ...

Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

...ted to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, mpm Capital, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, and Genzyme Corporation. For additional information, access our website...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...Company's Chief Financial Officer on a part-time basis. In support of Mr. Kailian's appointment, four of the Company's largest shareholders, mpm Capital, Great Point Partners, Oxford Biosciences and Venrock, agreed to a six-month lock-up agreement. The Board has commenced a search fo...

Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema

... Nordic Biotech II K/S and mpm BioVentures close on additional $6 million ...or Nordic Biotech II K/S and with participation by mpm BioVentures. Since its founding in 1997, Arriva ha... Biotech II KS and from our earlier lead investor, mpm Capital, allows us to continue the development of ...

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

...eregene was launched in January 2001 and is a former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, mpm Capital, Investor Growth Capital and Cell Genesys as well as Hamilton BioVentures and California Technology Partners. ...

Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis

...ted to result in safer and more effective products for multiple sclerosis and pemphigus vulgaris. Current investors include New Enterprise Associates, mpm Capital, Prism Venture Partners, Vanguard Ventures, Hunt Ventures, Boston Medical Investors, Silicon Valley Bank Capital, Itochu Corporation, and Genz...

MPM in Medical Products

BP-Tel™ Transtelephonic BP Monitor

Description:...f ther patient's homes. With its built-in proprietary communicator, BP-TEL automatically transmits data over the patient's home telephone line to the mpm Receiving Center....
Company:Aerotel Medical Systems Ltd.

MPM - Medical Parameters Monitoring System

Description:...llow-up care of the chronically ill. With Aerotels mpm equipment, patients can sit in the comfort of thei...l monitoring procedures in their offices. With the mpm system, data is automatically recorded and transfe...nitoring service center. Using Aerotels supporting mpm software, operators at the monitoring service cent...
Company:Aerotel Medical Systems Ltd.

MPM in Biological News

Researchers use multiphoton microscopy to watch chromosomes in action

... to image living salivary gland tissue of Drosophila (fruit flies). Unlike other methods, which lack penetrating power and can damage the specimen, mpm delivers crisp, clear images, even in thicker tissue samples like Drosophila salivary glands. The research was ultimately possible thanks to the ...

MPM in Biological Technology

VaxGen Addresses MPM Claims in Letter to Stockholders

Seeks to Correct the Record and Provide Accurate Information to Stockholders SOUTH SAN FRANCISCO, Calif., Dec. 20 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) Dear Stockholder: ...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

...ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, mpm Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE ) as well as Hamilton BioVentures and California Technology Partners. ...

iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming

...iPierian has secured a $10 million investment from mpm Capital, which will augment the original $20 milli...id Dr. Ashley Dombkowski, the managing director at mpm Capital who co-founded Pierian along with mpm managing director Robert Millman. Dr. Dombkowski ...

Valeritas Announces Appointment of New CEO

...n, Executive Chairman of the Board, Valeritas, Inc and Managing Director of mpm Capital. "She exhibits a broad range of experience and leadership qualitie...facility in Shrewsbury, Massachusetts. Valeritas primary investors include: mpm Capital, Pitango Venture Capital, Abingworth, US Venture Partners, Onset Ve...

Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million

... investors," said Timothy P. Noyes, President and CEO of Proteon. The initial closing of the Series B financing in March included new investors mpm Bio IV NVS Strategic Fund L.P. and Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism Vent...

Metabolex Announces Election of Kurt von Emster to Board of Directors

... From November 2000 to March 2009, Mr. von Emster was Managing Director of mpm BioEquities and a Portfolio Manager for the mpm BioEquities Fund. From July 1989 to November 2000, Mr. von Emster was with...

Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company

...ed a $38 million Series B equity financing, led by mpm Capital on behalf of the mpm Bio IV NVS Strategic Fund L.P. This announcement ...The Series B financing includes new investors, the mpm Bio IV NVS Strategic Fund L.P. and the Vectis Heal...

Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss

... NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by mpm Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use ...

TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing

...unced that it has raised 37 million USD through the private placement of preferred C stock from its existing shareholders and new investors, including mpm Capital, National Development Fund, YFY group, Taiwan Sugar Corporation, Yao-Hwa Glass Management Commission and Taiwan Global BioFund. This new round...

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

... ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, mpm Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE ) as well as Hamilton BioVentures and California Technology Partners. ...